Trial Profile
A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Jan 2014
Price :
$35
*
At a glance
- Drugs Difamilast (Primary) ; Tacrolimus
- Indications Atopic dermatitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 25 Jan 2014 New trial record